Leerink Partners Reiterates Outperform Following Globus Medical's (GMED) Strong 4Q

February 25, 2016 7:26 AM

Leerink Partners maintained an Outperform rating on Globus Medical (NYSE: GMED), and cut the price target to $29.00 (from $32.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found